Approved for 1 INDICATIONS AND USAGE COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 ). 12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits…
Loading full data from Know Your Drugs Institute…